- Home
- DXCM vs ILMN Comparison
DXCM vs ILMN Comparison
Compare DXCM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXCM
- ILMN
- Stock Information
- Founded
- DXCM 1999
- ILMN 1998
- Country
- DXCM United States
- ILMN United States
- Employees
- DXCM N/A
- ILMN N/A
- Industry
- DXCM Medical/Dental Instruments
- ILMN Medical Specialities
- Sector
- DXCM Health Care
- ILMN Health Care
- Exchange
- DXCM Nasdaq
- ILMN Nasdaq
- Market Cap
- DXCM 28.0B
- ILMN 23.6B
- IPO Year
- DXCM 2005
- ILMN 2000
- Fundamental
- Price
- DXCM $80.57
- ILMN $134.96
- Analyst Decision
- DXCM Buy
- ILMN Buy
- Analyst Count
- DXCM 17
- ILMN 17
- Target Price
- DXCM $98.00
- ILMN $163.12
- AVG Volume (30 Days)
- DXCM 3.2M
- ILMN 2.1M
- Earning Date
- DXCM 02-06-2025
- ILMN 02-06-2025
- Dividend Yield
- DXCM N/A
- ILMN N/A
- EPS Growth
- DXCM 83.21
- ILMN N/A
- EPS
- DXCM 1.67
- ILMN N/A
- Revenue
- DXCM $3,954,000,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- DXCM $13.10
- ILMN N/A
- Revenue Next Year
- DXCM $14.74
- ILMN $4.05
- P/E Ratio
- DXCM $48.33
- ILMN N/A
- Revenue Growth
- DXCM 16.19
- ILMN N/A
- 52 Week Low
- DXCM $62.34
- ILMN $97.36
- 52 Week High
- DXCM $142.00
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- DXCM 59.55
- ILMN 40.09
- Support Level
- DXCM $74.50
- ILMN $130.31
- Resistance Level
- DXCM $80.83
- ILMN $137.69
- Average True Range (ATR)
- DXCM 2.46
- ILMN 5.13
- MACD
- DXCM -0.01
- ILMN -1.03
- Stochastic Oscillator
- DXCM 86.59
- ILMN 21.69
About DXCM DexCom Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.